A huge sigh of relief accompanied Roche's announcement Mar. 2 that the keenly-awaited Phase III APHINITY trial showed that Perjeta (pertuzumab), combined with Herceptin (trastuzumab) and chemotherapy, extended disease-free survival in patients with HER2-positive early breast cancer when compared with Herceptin and chemo alone, and that no new safety signals were seen.
APHINITY's aim was to show that adding Perjeta would significantly improve invasive disease-free survival rates in women with early HER2-positive breast cancer